 Genetic Therapy
"Genetic Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
| Descriptor ID |
D015316
|
| MeSH Number(s) |
E02.095.301 E05.393.420.301
|
| Concept/Terms |
Genetic Therapy- Genetic Therapy
- Genetic Therapies
- Therapies, Genetic
- Therapy, Genetic
- Therapy, DNA
- DNA Therapy
Genetic Therapy, Somatic- Genetic Therapy, Somatic
- Genetic Therapies, Somatic
- Somatic Genetic Therapies
- Somatic Genetic Therapy
- Therapies, Somatic Genetic
- Therapy, Somatic Genetic
Genetic Therapy, Gametic- Genetic Therapy, Gametic
- Gametic Genetic Therapies
- Gametic Genetic Therapy
- Genetic Therapies, Gametic
- Therapies, Gametic Genetic
- Therapy, Gametic Genetic
|
Below are MeSH descriptors whose meaning is more general than "Genetic Therapy".
Below are MeSH descriptors whose meaning is more specific than "Genetic Therapy".
This graph shows the total number of publications written about "Genetic Therapy" by people in this website by year, and whether "Genetic Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 0 | 6 | | 1996 | 5 | 1 | 6 | | 1997 | 3 | 5 | 8 | | 1998 | 4 | 1 | 5 | | 1999 | 2 | 5 | 7 | | 2000 | 5 | 4 | 9 | | 2001 | 3 | 2 | 5 | | 2002 | 6 | 4 | 10 | | 2003 | 6 | 7 | 13 | | 2004 | 5 | 2 | 7 | | 2005 | 7 | 4 | 11 | | 2006 | 1 | 6 | 7 | | 2007 | 5 | 3 | 8 | | 2008 | 10 | 5 | 15 | | 2009 | 9 | 3 | 12 | | 2010 | 2 | 3 | 5 | | 2011 | 4 | 3 | 7 | | 2012 | 4 | 1 | 5 | | 2013 | 1 | 4 | 5 | | 2014 | 8 | 8 | 16 | | 2015 | 0 | 3 | 3 | | 2016 | 2 | 6 | 8 | | 2017 | 4 | 1 | 5 | | 2018 | 6 | 2 | 8 | | 2019 | 2 | 5 | 7 | | 2020 | 5 | 4 | 9 | | 2021 | 5 | 5 | 10 | | 2022 | 2 | 3 | 5 | | 2023 | 1 | 10 | 11 | | 2024 | 6 | 3 | 9 | | 2025 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Genetic Therapy" by people in Profiles.
-
Tamura S, Nelson AD, Spratt PWE, Hamada EC, Zhou X, Kyoung H, Li Z, Arnould C, Barskyi V, Krupkin B, Young K, Zhao J, Holden SS, Sahagun A, Keeshen CM, Lu C, Ben-Shalom R, Taloma SE, Schamiloglu S, Li YC, Min L, Jenkins PM, Pan JQ, Paz JT, Sanders SJ, Matharu N, Ahituv N, Bender KJ. CRISPR activation for SCN2A-related neurodevelopmental disorders. Nature. 2025 Oct; 646(8086):983-991.
-
Ibel A, Bhardwaj R, Yilmaz DE, Kong S, Wendlinger S, Cordero C, Papaioannou D, Papazian M, Schönauer R, Meng Q, Eckardt KU, Hassan F, Volpe I, Klämbt V, Halbritter J, Fedeles S, Krappitz M, Kaminski MM. In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease. Mol Ther. 2025 Nov 05; 33(11):5373-5382.
-
Mayer-Hamblett N, Kerper NR, Clancy JP, Davies JC, Taylor-Cousar JL, Donaldson SH, Bell SC, Jain R, Simmonds NJ, Mall MA, Goss CH, Rayment JH, Setiawan L, Pilewski JM. Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials. Lancet Respir Med. 2025 Dec; 13(12):1108-1118.
-
Cheerie D, Meserve MM, Beijer D, Kaiwar C, Newton L, Taylor Tavares AL, Verran AS, Sherrill E, Leonard S, Sanders SJ, Blake E, Elkhateeb N, Gandhi A, Liang NSY, Morgan JT, Verwillow A, Verheijen J, Giles A, Williams S, Chopra M, Croft L, Dafsari HS, Davidson AE, Friedman J, Gregor A, Haque B, Lechner R, Montgomery KA, Ryten M, Schober E, Siegel G, Sullivan PJ, Whittle EF, Zardetto B, Yu TW, Synofzik M, Aartsma-Rus A, Costain G, Lauffer MC. Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments. Am J Hum Genet. 2025 May 01; 112(5):975-983.
-
Du X, Nakanishi H, Yamada T, Sin Y, Minegishi K, Motohashi N, Aoki Y, Itaka K. Polyplex Nanomicelle-Mediated Pgc-1a4 mRNA Delivery Via Hydrodynamic Limb Vein Injection Enhances Damage Resistance in Duchenne Muscular Dystrophy Mice. Adv Sci (Weinh). 2025 Apr; 12(16):e2409065.
-
Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 May; 43(5):583-594.
-
Jiang D, Wang M, Wheeler AP, Croteau SE. 2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders. Am J Hematol. 2025 Apr; 100(4):666-684.
-
Cao M, Katial R, Liu Y, Lu X, Gu Q, Chen C, Liu K, Zhu Z, Marshall MR, Yu Y, Wang Z. Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials. Gene Ther. 2025 May; 32(3):223-236.
-
Sanati M, Figueroa-Espada CG, Han EL, Mitchell MJ, Yavari SA. Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers. ACS Nano. 2024 12 24; 18(51):34425-34463.
-
Kim-McManus O, Gleeson JG, Mignon L, Smith Fine A, Yan W, Nolen N, Demarest S, Berry-Kravis E, Finkel R, Leonard S, Finlayson S, Augustine E, Lyon GJ, Schule R, Yu T. A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases. Nat Commun. 2024 11 12; 15(1):9802.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|